Answers are grounded in this paper and cite their sources.
Thrombotic microangiopathy is an uncommon but reported adverse effect of a variety of antineoplastic drugs, including chemotherapy agents such as mitomycin C and gemcitabine, and newer targeted agents such as the vascular endothelial growth factor inhibitors. We present a review of thrombotic microangiopathy associated with antineoplastic agents and its implications in current cancer therapy.
No takes yet. Share an insight, caveat, or question.
Garcia et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: